Dopo l'orario di chiusura: 2.42 0.03 +1.26%

Perspective Therapeutics Inc (CATX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione Frazionamento azionario

Perspective Therapeutics Inc Borsa (CATX) Ultime notizie

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc Borsa (CATX) Ultime notizie

Two Sigma Investments LP Takes $2.08 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial - Insider Monkey

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-?-NET at the 2025 ASCO Annual Meeting | CATX Stock News - GuruFocus

Perspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025 - Nasdaq

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - Yahoo Finance

Millennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Neuroendocrine Tumors Market: Epidemiology, Therapies, - openPR.com

Perspective Therapeutics Holds Annual Stockholders Meeting - TipRanks

Perspective Therapeutics Announces Voting Results - Investing.com

Northern Trust Corp Acquires 13,115 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Janus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages - Defense World

Equities Analysts Offer Predictions for CATX Q1 Earnings - Defense World

HC Wainwright Has Pessimistic Outlook of CATX Q3 Earnings - Defense World

Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - MSN

Head-To-Head Review: Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) - Defense World

Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com Nigeria

Mercer Global Advisors Inc. ADV Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Perspective Therapeutics Reports Q1 2025 Earnings - TipRanks

Perspective Therapeutics (CATX) Rating Maintained, Price Target Lowered | CATX Stock News - GuruFocus

Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating - marketscreener.com

Oppenheimer cuts CATX stock price target to $15, maintains Outperform By Investing.com - Investing.com South Africa

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | CATX Stock News - GuruFocus

Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating - marketscreener.com

Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World

Oppenheimer cuts CATX stock price target to $15, maintains Outperform - Investing.com

Perspective Therapeutics: Q1 Earnings Snapshot - The Washington Post

Perspective Therapeutics Inc (CATX) Q1 2025 Earnings: EPS Loss of $0.25 Beats Estimate, Revenue of $0.3M Exceeds Expectations - GuruFocus

Perspective Therapeutics Reports Q1 2025 Results and Updates - TipRanks

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - The Manila Times

Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting - Nasdaq

Perspective Therapeutics (CATX) Prepares for Q1 Earnings Announcement - GuruFocus

Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Barclays PLC - Defense World

Mariner LLC Invests $150,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Perspective Therapeutics Inc (AMEX: CATX): Down -84.76% In 2025, Outlook Remains Negative - Stocksregister

Legal & General Group Plc Has $155,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Perspective Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times

JPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors - marketscreener.com

Perspective Therapeutics (CATX) Launches Initial Patient Treatme - GuruFocus

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors - The Manila Times

Groundbreaking Cancer Treatment Trial Launches: Perspective's FAP-α Targeted Alpha Therapy Shows Promise - Stock Titan

Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World

A History of Outperforming Analyst Forecasts and Beating the Odds: Perspective Therapeutics Inc (CATX) - Sete News

A company insider recently bought 22,026 shares of Perspective Therapeutics Inc [CATX]. Should You Buy? - knoxdaily.com

Perspective Therapeutics Inc (CATX)’s stock rises to 2.33 per share - uspostnews.com

Perspective Therapeutics Announces Acceptance of VMT-?-NET and V - GuruFocus

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - The Manila Times

Perspective Therapeutics Announces Acceptance of Key Radiopharmaceutical Data for Presentation at ASCO 2025 Annual Meeting - Nasdaq

Major Breakthrough: Perspective Therapeutics to Present Novel Cancer Treatment Data at ASCO 2025 - Stock Titan

CATX Stock on the Rise: A Promising Investment - investchronicle.com

Simile a CATX